TN2013000472A1 - Induction of immune tolerance by using methotrexate - Google Patents

Induction of immune tolerance by using methotrexate

Info

Publication number
TN2013000472A1
TN2013000472A1 TNP2013000472A TN2013000472A TN2013000472A1 TN 2013000472 A1 TN2013000472 A1 TN 2013000472A1 TN P2013000472 A TNP2013000472 A TN P2013000472A TN 2013000472 A TN2013000472 A TN 2013000472A TN 2013000472 A1 TN2013000472 A1 TN 2013000472A1
Authority
TN
Tunisia
Prior art keywords
methotrexate
induction
immune tolerance
immune responses
responses
Prior art date
Application number
TNP2013000472A
Other languages
English (en)
French (fr)
Inventor
Alexandra Joseph
Susan Richards
Melanie Ruzek
Richard Garman
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000472(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of TN2013000472A1 publication Critical patent/TN2013000472A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
TNP2013000472A 2011-05-16 2013-11-13 Induction of immune tolerance by using methotrexate TN2013000472A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486697P 2011-05-16 2011-05-16
PCT/US2012/036405 WO2012158362A1 (en) 2011-05-16 2012-05-03 Induction of immune tolerance by using methotrexate

Publications (1)

Publication Number Publication Date
TN2013000472A1 true TN2013000472A1 (en) 2015-03-30

Family

ID=47177257

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000472A TN2013000472A1 (en) 2011-05-16 2013-11-13 Induction of immune tolerance by using methotrexate

Country Status (28)

Country Link
US (3) US20140135337A1 (enExample)
EP (2) EP2709627B1 (enExample)
JP (3) JP6174572B2 (enExample)
KR (3) KR20140040744A (enExample)
CN (4) CN113209288A (enExample)
AU (1) AU2012256281B2 (enExample)
BR (1) BR112013029501A2 (enExample)
CA (1) CA2835819A1 (enExample)
CL (1) CL2013003298A1 (enExample)
CO (1) CO6841993A2 (enExample)
DO (1) DOP2013000268A (enExample)
EC (1) ECSP13013081A (enExample)
ES (1) ES2836823T3 (enExample)
GT (1) GT201300278A (enExample)
IL (2) IL229245B (enExample)
MA (1) MA35165B1 (enExample)
MX (1) MX2013013445A (enExample)
MY (1) MY173304A (enExample)
NI (1) NI201300121A (enExample)
PE (1) PE20140469A1 (enExample)
PH (1) PH12013502256A1 (enExample)
PT (1) PT2709627T (enExample)
RU (1) RU2674036C2 (enExample)
SG (1) SG194802A1 (enExample)
TN (1) TN2013000472A1 (enExample)
UA (1) UA117556C2 (enExample)
WO (1) WO2012158362A1 (enExample)
ZA (1) ZA201308315B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809282B2 (en) * 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
MX373641B (es) 2011-04-29 2020-05-04 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
EP2709627B1 (en) 2011-05-16 2020-09-23 Genzyme Corporation Induction of immune tolerance by using methotrexate
CN105283175A (zh) * 2013-05-03 2016-01-27 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
EA201592273A1 (ru) * 2013-06-04 2016-09-30 Селекта Байосайенсиз, Инк. Повторное введение неиммуносупрессивных антигенспецифических иммунотерапевтических средств
KR20170045344A (ko) 2014-09-07 2017-04-26 셀렉타 바이오사이언시즈, 인크. 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
JP2016213236A (ja) * 2015-04-30 2016-12-15 日東電工株式会社 半導体装置用フィルム、及び、半導体装置の製造方法
JP7523909B2 (ja) 2017-03-11 2024-07-29 セレクタ バイオサイエンシーズ インコーポレーテッド 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
WO2018209300A1 (en) * 2017-05-12 2018-11-15 Duke University Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy
TWI821227B (zh) * 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記
IL295415A (en) 2020-02-08 2022-10-01 Genzyme Corp Compositions and methods for treating pompe disease
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080325A (en) 1976-11-17 1978-03-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of methotrexate
US4558690A (en) 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
US5108987A (en) 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
DE4000154A1 (de) 1990-01-04 1991-07-11 Symbiotec Gmbh Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
WO2005085294A1 (ja) 2004-03-05 2005-09-15 Denki Kagaku Kogyo Kabushiki Kaisha ヒアルロン酸−メトトレキサート結合体
US7884196B2 (en) 2004-10-06 2011-02-08 Oliver Lawless Vaccine composition comprising methylated DNA and immunomodulatory motifs
EP2918269A1 (en) * 2006-03-02 2015-09-16 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
WO2008094937A2 (en) 2007-01-29 2008-08-07 Joslin Diabetes Center, Inc. Methods of modulating angiogenesis
US20090155207A1 (en) * 2007-11-29 2009-06-18 Hariri Robert J Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
CA2740077A1 (en) 2008-10-08 2010-04-15 Cambridge Enterprise Limited Methods and compositions for diagnosis and treatment
MX2011004870A (es) 2008-11-07 2011-09-06 4Sc Ag Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes.
EP2709627B1 (en) 2011-05-16 2020-09-23 Genzyme Corporation Induction of immune tolerance by using methotrexate

Also Published As

Publication number Publication date
JP2017141236A (ja) 2017-08-17
KR20140040744A (ko) 2014-04-03
RU2674036C2 (ru) 2018-12-04
CL2013003298A1 (es) 2014-07-25
AU2012256281B2 (en) 2017-06-15
US20140135337A1 (en) 2014-05-15
AU2012256281A1 (en) 2013-11-28
JP6694020B2 (ja) 2020-05-13
PT2709627T (pt) 2020-12-24
EP2709627B1 (en) 2020-09-23
KR102316283B1 (ko) 2021-10-21
US20200360385A1 (en) 2020-11-19
CN109620830A (zh) 2019-04-16
WO2012158362A1 (en) 2012-11-22
CO6841993A2 (es) 2014-01-20
NZ617575A (en) 2016-10-28
PE20140469A1 (es) 2014-04-23
EP2709627A4 (en) 2014-11-12
JP6174572B2 (ja) 2017-08-02
JP2014513722A (ja) 2014-06-05
UA117556C2 (uk) 2018-08-27
KR102163285B1 (ko) 2020-10-08
ZA201308315B (en) 2014-07-30
EP3824890A1 (en) 2021-05-26
RU2013155618A (ru) 2015-06-27
IL229245A0 (en) 2014-01-30
MA35165B1 (fr) 2014-06-02
ECSP13013081A (es) 2015-04-30
NI201300121A (es) 2014-02-28
NZ716716A (en) 2018-06-29
MX2013013445A (es) 2014-07-28
CN113209288A (zh) 2021-08-06
IL229245B (en) 2020-08-31
SG194802A1 (en) 2013-12-30
EP2709627A1 (en) 2014-03-26
BR112013029501A2 (pt) 2017-01-24
DOP2013000268A (es) 2014-01-31
KR20190132551A (ko) 2019-11-27
GT201300278A (es) 2015-02-12
JP2018184466A (ja) 2018-11-22
MY173304A (en) 2020-01-14
NZ742216A (en) 2018-10-26
CN103648501A (zh) 2014-03-19
CN110124039A (zh) 2019-08-16
IL276879B (en) 2022-06-01
JP6381707B2 (ja) 2018-08-29
KR20200116543A (ko) 2020-10-12
PH12013502256A1 (en) 2022-04-08
ES2836823T3 (es) 2021-06-28
US20230372347A1 (en) 2023-11-23
US11672802B2 (en) 2023-06-13
IL276879A (en) 2020-10-29
CA2835819A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
TN2013000472A1 (en) Induction of immune tolerance by using methotrexate
TN2015000050A1 (en) Methods of treating a tauopathy
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
SG194701A1 (en) Anti-cd40 antibodies and methods of use
PH12014501844B1 (en) Peptidomimetic macrocycles
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
SG10201804338PA (en) Anti-fcrh5 antibodies
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
WO2012173846A3 (en) Peptidomimetic macrocycles
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
HK1216754A1 (zh) 抗-rankl抗体及其使用方法
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.